Minovar announced that the pharmaceutical ingredient propofol tenofovir fumarate from Zhejiang Menova Pharmaceutical Chemical Co., Ltd., passed the technical review by the Drug Evaluation Center of the State Drug Administration, and the registration number changed to “A” status. The drug is suitable for the treatment of chronic hepatitis B in adults and adolescents. Its raw materials have met national drug evaluation technical standards and can be sold to the domestic market. Passing this review will enrich the product line, help expand business areas and enhance the advantages of integrated production.